Athira Pharma, Inc. — Director's Dealing 2022

Jul 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-06-29

Reporting Person: PERCEPTIVE ADVISORS LLC (Director, 10% Owner)
Reporting Person: PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Director, 10% Owner)
Reporting Person: EDELMAN JOSEPH (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-29	Common Stock	P	270000	$2.99	Acquired	3695916	Indirect
2022-06-30	Common Stock	P	1101362	$2.99	Acquired	4797278	Indirect

Footnotes

F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.83 to $3.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

F2: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.87 to $3.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of purchased at each separate price within such range.

F3: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.